

Special Issue

Advances in Oral Vaccine Development

Message from the Guest Editor

Most human pathogens invade via a mucosal site. Through oral vaccination, it is possible to generate protective immune responses tailored towards mucosal immune defence. Practical considerations make oral vaccines ideal for paediatric administration, as well as for integration into mass administration programmes. The use of trivalent and bivalent oral polio vaccines led to the eradication of wild poliovirus type 2 in 2015 and wild poliovirus type 2 in 2019. These successes highlight the potential impact of oral vaccination programmes, and we feel that research should be supported towards the development of novel oral vaccines targeting bacterial and viral pathogens. With this in mind, we invite researchers with new knowledge of relevance to the field of oral vaccine development to submit to this Special Issue, entitled “Advances in Oral Vaccine Development”. There are no limitations on the paper type; original research articles, reviews, or short communications are warmly welcome.

Guest Editor

Dr. Shaun Pennington
Liverpool School of Tropical Medicine, Liverpool, UK

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/157920

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).